Celularity (CELU) Competitors $2.20 +0.06 (+2.80%) Closing price 04:00 PM EasternExtended Trading$2.16 -0.04 (-1.59%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELU vs. NLTX, PROK, ALMS, ELDN, CYBN, TIL, PBYI, VYGR, TLSA, and IMABShould you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Neoleukin Therapeutics (NLTX), ProKidney (PROK), Alumis (ALMS), Eledon Pharmaceuticals (ELDN), Cybin (CYBN), Instil Bio (TIL), Puma Biotechnology (PBYI), Voyager Therapeutics (VYGR), Tiziana Life Sciences (TLSA), and I-Mab (IMAB). These companies are all part of the "pharmaceutical products" industry. Celularity vs. Its Competitors Neoleukin Therapeutics ProKidney Alumis Eledon Pharmaceuticals Cybin Instil Bio Puma Biotechnology Voyager Therapeutics Tiziana Life Sciences I-Mab Celularity (NASDAQ:CELU) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Is CELU or NLTX more profitable? Neoleukin Therapeutics has a net margin of 0.00% compared to Celularity's net margin of -106.77%. Neoleukin Therapeutics' return on equity of -37.22% beat Celularity's return on equity.Company Net Margins Return on Equity Return on Assets Celularity-106.77% -271.88% -42.82% Neoleukin Therapeutics N/A -37.22%-30.91% Which has stronger valuation & earnings, CELU or NLTX? Neoleukin Therapeutics has lower revenue, but higher earnings than Celularity. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelularity$54.22M0.97-$57.89M-$2.65-0.83Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-7.25 Which has more volatility and risk, CELU or NLTX? Celularity has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Does the media refer more to CELU or NLTX? In the previous week, Celularity had 2 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 2 mentions for Celularity and 0 mentions for Neoleukin Therapeutics. Celularity's average media sentiment score of 0.63 beat Neoleukin Therapeutics' score of 0.00 indicating that Celularity is being referred to more favorably in the media. Company Overall Sentiment Celularity Positive Neoleukin Therapeutics Neutral Do insiders and institutionals believe in CELU or NLTX? 19.0% of Celularity shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 22.1% of Celularity shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryCelularity and Neoleukin Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELU vs. The Competition Export to ExcelMetricCelularityMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.69M$2.93B$5.50B$9.39BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-0.8320.3128.1019.86Price / Sales0.97261.57402.2879.25Price / CashN/A42.3835.5357.53Price / Book5.957.838.265.72Net Income-$57.89M-$55.11M$3.24B$257.80M7 Day Performance1.85%2.18%0.50%1.06%1 Month Performance26.44%12.98%7.99%11.30%1 Year Performance-31.03%1.98%28.68%17.00% Celularity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELUCelularity0.131 of 5 stars$2.20+2.8%N/A-30.5%$52.69M$54.22M-0.83220Upcoming EarningsNLTXNeoleukin TherapeuticsN/A$20.09+1.7%N/A-53.1%$188.81MN/A-6.4690PROKProKidney3.3765 of 5 stars$0.61-4.8%$3.50+477.1%+54.8%$186.51M$306K-1.013Analyst ForecastGap UpALMSAlumis3.2927 of 5 stars$3.31-2.6%$22.86+590.5%-69.0%$184.98MN/A0.00N/AELDNEledon Pharmaceuticals1.9955 of 5 stars$3.11+1.0%$9.00+189.4%+33.6%$184.44MN/A-1.4810Positive NewsAnalyst RevisionCYBNCybin2.8283 of 5 stars$7.87-0.9%$86.00+992.8%N/A$181.20MN/A-1.8050News CoverageTILInstil Bio3.4439 of 5 stars$23.64-14.0%$119.00+403.4%+94.1%$180.37MN/A-1.97410Positive NewsHigh Trading VolumePBYIPuma Biotechnology4.2268 of 5 stars$3.54-1.1%$7.00+97.7%-12.9%$177.68M$230.50M4.60200VYGRVoyager Therapeutics4.0135 of 5 stars$3.04-5.0%$13.39+340.5%-64.0%$177.08M$80M-2.08100News CoverageTLSATiziana Life Sciences1.1802 of 5 stars$1.53+1.3%N/A+85.2%$176.44MN/A0.008IMABI-Mab2.859 of 5 stars$2.09-2.8%$6.00+187.1%+31.9%$175.57M$3.89M0.00380Gap Down Related Companies and Tools Related Companies NLTX Competitors PROK Competitors ALMS Competitors ELDN Competitors CYBN Competitors TIL Competitors PBYI Competitors VYGR Competitors TLSA Competitors IMAB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELU) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
